About Respiratorius

About company

Respiratorius AB develops new effective drugs for cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. The company also runs a project within PET imaging with application in cardiovascular diagnostics. The company is currently conducting clinical development of a drug project (VAL-001), for the treatment of Diffust Large Cell B cell lymphoma. In COPD and asthma, Respiratorius has focused on a new class of patent-pending drug substances, which compared to existing therapies have a superior ability to relax the small airways. The substances, which utilize a new mechanism of action, have been developed via ex-vivo experiments on human lung tissue in the company's proprietary measuring and testing chamber.